The significance of an increase in soluble interleukin-2 receptor level in colorectal cancer and its biological regulating role in the physiological switching of the immune response cytokine network from TH1 to TH2 and back

被引:43
作者
Berghella, AM [1 ]
Pellegrini, P [1 ]
Del Beato, T [1 ]
Marini, M [1 ]
Tomei, E [1 ]
Adorno, D [1 ]
Casciani, CU [1 ]
机构
[1] Univ Aquila, Ist CNR Tipizzaz Tissutale & Problemi Dialisi, I-67100 Laquila, Italy
关键词
colorectal cancer; sIL-2R; TH1; TH2; cytokine network;
D O I
10.1007/s002620050439
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Current research has still not clarified the biological role of soluble interleukin(IL)-2 receptor (sIL-2R) and the significance of its increase in the serum of colon cancer patients compared to healthy subjects. To address these questions at the immunological level in a group of patients and healthy subjects, we determined the sIL-2R level in the serum and its release from peripheral blood mononuclear cells (PBMC) as a function of tumour necrosis factor (TNF) alpha, IL-1 alpha, IL-1 beta, IL-2, interferon (IFN) gamma, IL-4, IL-6 and IL-10 levels in the serum and PBMC production; and PBMC proliferative responses to IL-2, IL-4 and anti-CD3 monoclonal antibody (CD3), variously combined. The level of sIL-2R in patients' serum was higher than in healthy subjects and correlated with the stage of advancement. Moreover, while in healthy subjects the serum level of sIL-2R was not significantly correlated with other parameters, in patients it was positively related to IL-4, IL-6 and IL-10 serum levels, PBMC IL-4 production and to the PBMC proliferative response to CD3 and CD3+IL-2; it was negatively correlated to IL-2 serum level and IL-1 beta PBMC release. A negative connection between IFN?I serum level and the PBMC production of sIL-2R was also found. This suggests that the increase of sIL-2R in the serum of patients, compared to healthy subjects, is involved in the inappropriate expansion of the T helper (TH2) suppressive immune response, which we previously reported. The multivariate statistical method supported the above suggestions and we also found that, in healthy subjects, the up- and down-regulation of sIL-2R in the serum within the physiological ranges seems to have a regulating role in the relationships between TNF alpha, IFN gamma and IL-4, IL-6, contributing to the operation of the cytokine network between TH1 and TH2 cells. However, in patients compared to healthy subjects the increased sIL-2R serum level seems to direct the immune response towards a suppressive type, which may be due to an alteration in the above-mentioned physiological regulating role.
引用
收藏
页码:241 / 249
页数:9
相关论文
共 39 条
[31]   REGULATION OF ANTIBODY ISOTYPE SECRETION BY SUBSETS OF ANTIGEN-SPECIFIC HELPER T-CELLS [J].
STEVENS, TL ;
BOSSIE, A ;
SANDERS, VM ;
FERNANDEZBOTRAN, R ;
COFFMAN, RL ;
MOSMANN, TR ;
VITETTA, ES .
NATURE, 1988, 334 (6179) :255-258
[32]  
STREET NE, 1990, J IMMUNOL, V144, P1629
[33]   INTERLEUKIN-4 SUPPRESSES INTERLEUKIN-2 AND INTERFERON-GAMMA PRODUCTION BY NAIVE T-CELLS STIMULATED BY ACCESSORY CELL-DEPENDENT RECEPTOR ENGAGEMENT [J].
TANAKA, T ;
HULI, J ;
SEDER, RA ;
FAZEKAS DE ST GROTH, B ;
PAUL, WE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (13) :5914-5918
[34]  
THOMSON AW, 1994, CYTOKINE HDB
[35]   Release of sIL-2R alpha from and activation of native human peripheral blood mononuclear cells by recombinant IL-15 [J].
TreiberHeld, S ;
Stewart, DM ;
Barraclough, HA ;
Kurman, CC ;
Nelson, DL .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1996, 80 (01) :67-75
[36]   DISSECTION OF THE PROLIFERATIVE AND DIFFERENTIATIVE SIGNALS CONTROLLING MURINE CYTO-TOXIC T-LYMPHOCYTE RESPONSES [J].
WAGNER, H ;
HARDT, C ;
ROUSE, BT ;
ROLLINGHOFF, M ;
SCHEURICH, P ;
PFIZENMAIER, K .
JOURNAL OF EXPERIMENTAL MEDICINE, 1982, 155 (06) :1876-1881
[37]   Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma - Clinical and prognostic implications [J].
Wasik, MA ;
Vonderheid, EC ;
Bigler, RD ;
Marti, R ;
Lessin, SR ;
Polansky, M ;
Kadin, ME .
ARCHIVES OF DERMATOLOGY, 1996, 132 (01) :42-47
[38]  
WILLIAMS ME, 1990, J IMMUNOL, V144, P1208
[39]  
YAMASHITA N, 1989, J IMMUNOL, V143, P1518